title: Denosumab-related osteonecrosis of the jaws: successful management with a conservative surgical approach.
abstract: Denosumab-related osteonecrosis of the jaws (DRONJ) is a recently described entity that shares many common clinical and radiological features with bisphosphonate-related osteonecrosis of the jaws (BRONJ). The aim of the present study is to report a case of DRONJ affecting the anterior mandible of a 58-year-old male treated with denosumab to prevent skeletal-related events associated with prostate cancer. Conservative surgery in conjunction with antibiotic therapy and discontinuation of denosumab use were effective in managing the condition and the patient remains free of clinical and radiological changes after a 38 month follow-up.
authors: Resident, Oral and Maxillofacial Surgery, Pedro Ernesto University Hospital, State University of Rio de Janeiro, Brazil.
authors: Raphaela Capella
authors: RC
authors: de Souza Póvoa
authors: Resident, Oral and Maxillofacial Surgery, Pedro Ernesto University Hospital, State University of Rio de Janeiro, Brazil.
authors: Daniel Amaral Alves
authors: DA
authors: Marlierè
authors: Adjunct Professor, Oral and Maxillofacial Surgery, Pedro Ernesto University Hospital, State University of Rio de Janeiro, Brazil.
authors: Henrique Martins
authors: HM
authors: da Silveira
authors: Associate Professor, Oral Pathology, School of Dentistry, State University of Rio de Janeiro, Brazil.
authors: Fábio Ramoa
authors: FR
authors: Pires
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000000981:diagnostic imaging / Q000601:surgery*; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D003131:Combined Modality Therapy; D000069448:Denosumab / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D000900:Anti-Bacterial Agents; D050071:Bone Density Conservation Agents; D000069448:Denosumab
keywords: denosumab; jaw; mandible; osteonecrosis; receptor activator of nuclear factor kappa-B ligand (RANKL)